Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
BEXSON BIOMEDICAL, INC. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 2 distinct examiners, including VISHNYAKOVA, ELENA VLADIMIROVNA, who is the busiest examiner with 1 pending action. The portfolio spans 2 distinct art units, which indicates that the biomedical filings are being evaluated across different specialized technical groups at the patent office.
The distribution of 2 pending office actions across 2 distinct examiners and 2 distinct art units suggests a lack of examiner concentration. Each of the 2 examiners, including VISHNYAKOVA, ELENA VLADIMIROVNA, handles 1 pending action, requiring counsel to manage 2 different prosecution styles simultaneously. The presence of 2 examiners for 2 pending actions means that no single examiner's preferences will dictate the overall direction of the portfolio. Practitioners must monitor the specific trends in both art units to effectively navigate the 2 pending matters in the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VISHNYAKOVA, ELENA VLADIMIROVNA | 1 | 65.8% | +51.3% |
| PONTON, JAMES D | 1 | 79.9% | +32.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18009612 | SYSTEMS AND DEVICES FOR CONTROLLED DRUG DELIVERY | PONTON, JAMES D | 35d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18009612 | SYSTEMS AND DEVICES FOR CONTROLLED DRUG DELIVERY | PONTON, JAMES D | 35d |
| 18037515 | FLUMAZENIL FORMULATIONS FOR SUBCUTANEOUS INJECTION AND METHODS OF TREATMENT USING GABA RECEPTOR MODULATORS | VISHNYAKOVA, ELENA VLADIMIROVNA | — |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| 3783 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18037515 | FLUMAZENIL FORMULATIONS FOR SUBCUTANEOUS INJECTION AND METHODS OF TREATMENT USING GABA RECEPTOR MODULATORS | VISHNYAKOVA, ELENA VLADIMIROVNA | 1691 | §102DPOther | Non-Final OA | — | Pending | May 17, 2023 |
| 18009612 | SYSTEMS AND DEVICES FOR CONTROLLED DRUG DELIVERY | PONTON, JAMES D | 3783 | §102§103§112 | Non-Final OA | 35d | Pending | Dec 09, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial